BAFF receptor (BCMA), an immunoregulatory agent
AssigneesBiogen Idec MA Inc., Apoxis SA
InventorsBrowning Jeffrey, Ambrose Christine, MacKay Fabienne, Tschopp Jurg, Schneider Pascal, Thompson Jeffrey
Life of this patent
Estimating the term…
Abstract
A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
Claims21
A method of inhibiting B-cell growth in an animal comprising the step of administering a therapeutically effective amount of a composition selected from the group consisting of:
- (a) a BAFF-R polypeptide or fragment thereof;
- (b) a chimeric molecule comprising a BAFF-R polypeptide or fragment thereof fused to a heterologous amino acid sequence;
- and
- (c) an anti-BAFF-R antibody homolog.
A method of inhibiting immunoglobulin production in an animal comprising the step of administering a therapeutically effective amount of a composition selected from the group consisting of:
- (a) a BAFF-R polypeptide or fragment thereof;
- (b) a chimeric molecule comprising a BAFF-R polypeptide or fragment thereof fused to a heterologous amino acid sequence;
- and
- (c) an anti-BAFF-R antibody homolog.
A method of inhibiting dendritic cell-induced B-cell growth and maturation in an animal comprising the step of administering a therapeutically effective amount of a composition selected from the group consisting of:
- (a) a BAFF-R polypeptide or fragment thereof;
- (b) a chimeric molecule comprising a BAFF-R polypeptide or fragment thereof fused to a heterologous amino acid sequence;
- and
- (c) an anti-BAFF-R antibody homolog.
A method of treatment of an autoimmune disease comprising the step of administering a therapeutically effective amount of a composition selected from the group consisting of:
- (a) a BAFF-R polypeptide or fragment thereof;
- (b) a chimeric molecule comprising a BAFF-R polypeptide or fragment thereof fused to a heterologous amino acid sequence;
- and
- (c) an anti-BAFF-R antibody homolog.
A method of treating hypertension in an animal comprising the step of administering a therapeutically effective amount of a B-cell growth inhibitor selected from the group consisting of:
- (a) a BAFF-R polypeptide or fragment thereof;
- (b) a chimeric molecule comprising a BAFF-R polypeptide or fragment thereof fused to a heterologous amino acid sequence;
- and
- (c) an anti-BAFF-R antibody homolog.
A method of treating renal disorders in an animal comprising the step of administering a therapeutically effective amount of a B-cell growth inhibitor selected from the group consisting of:
- (a) a BAFF-R polypeptide or fragment thereof;
- (b) a chimeric molecule comprising a BAFF-R polypeptide or fragment thereof fused to a heterologous amino acid sequence;
- and
- (c) an anti-BAFF-R antibody homolog.
A method of treating B-cell lympho-proliferate disorders comprising the step of administering a therapeutically effective amount of a B-cell growth inhibitor selected from the group consisting of:
- (a) a BAFF-R polypeptide or fragment thereof;
- (b) a chimeric molecule comprising a BAFF-R polypeptide or fragment thereof fused to a heterologous amino acid sequence;
- and
- (c) an anti-BAFF-R antibody homolog.
A method of treating, suppressing or altering an immune response involving a signaling pathway between a BAFF-R and BAFF comprising the step of administering an effective amount of an agent capable of interfering with the association between the BAFF-R and BAFF.
A method of inhibiting inflammation comprising the step of administering a therapeutically effective amount of an antibody specific for a BAFF-R or an active fragment thereof.
A method of inhibiting inflammation comprising the step of administering a therapeutically effective amount of an antibody specific for a BAFF-R or an epitope thereof.
A pharmaceutical composition comprising a therapeutically effective amount of an isolated BAFF-R polypeptide or a fragment thereof and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.